Table 2.
Predictors for AF recurrence, in meta-analyses of randomized controlled trials
| Author, year | Predictor | Exposed/unexposed as in included MA | K | n/N | Metric | ES (95% CI) | P | PI include null value | I2 | SSE | ESB | High RoB | GLE | AMSTAR 2 quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Post-cardioversion | ||||||||||||||
| Cao, 2012 | Omega-3 fatty acids | Omega-3 fatty acids vs. control | 6 | 455/759 | OR | 0.626 (0.348, 1.127) | 0.118 | Yes | 66.43% | No | NP | >25 | N/S | Critically low |
| Lafuente, 2015 | Quinidine | Quinidine vs. control | 7 | 1158/1624 | OR | 0.508 (0.401, 0.401) | 0.000 | No | 0% | No | No | >25 | Moderate | High |
| Lafuente, 2015 | Disopyramide | Disopyramide vs. control | 2 | 89/146 | OR | 0.525 (0.271, 1.019) | 0.057 | NA | 0% | NA | NP | >25 | N/S | High |
| Lafuente, 2015 | Flecainide | Flecainide vs. control | 4 | 276/511 | OR | 0.350 (0.200, 0.615) | 0.0000 | No | 34.38% | No | No | >25 | Moderate | High |
| Lafuente, 2015 | Propafenone | Propafenone | 5 | 652/1098 | OR | 0.366 (0.282, 0.476) | 0.027 | Yes | 0% | No | NP | >25 | Moderate | High |
| Lafuente, 2015 | Class I others | Class I others vs. control | 3 | 1138/1383 | OR | 0.718 (0.422, 1.221) | 0.221 | Yes | 33.02% | No | NP | >25 | N/S | High |
| Lafuente, 2015 | Beta-blockers | Beta-blockers vs. control | 2 | 375/562 | OR | 0.432 (0.143, 1.300) | 0.135 | NA | 88.60% | NA | No | >25 | Low | High |
| Lafuente, 2015 | Amiodarone | Amiodarone vs. control | 6 | 471/812 | OR | 0.189 (0.141, 0.253) | 0.0000 | No | 0% | No | No | >25 | Moderate | High |
| Lafuente, 2015 | Azimilide | Azimilide vs. control | 4 | 1260/1602 | OR | 0.702(0.549, 0.897) | 0.0046 | Yes | 0% | No | No | >25 | Moderate | High |
| Lafuente, 2015 | Dofetilide | Dofetilide vs. control | 3 | 811/1183 | OR | 0.338(0.193, 0.593) | 0.0002 | Yes | 74.85% | Yes | NP | >25 | Moderate | High |
| Lafuente, 2015 | Dronedarone | Dronedarone vs. control | 2 | 1001/1443 | OR | 0.585(0.459, 0.745) | 0.0000 | NA | 0% | NA | NP | >25 | Moderate | High |
| Lafuente, 2015 | Sotalol | Sotalol vs. control | 13 | 2189/2758 | OR | 0.512(0.404, 0.647) | 0.0000 | No | 42.71% | No | Yes | >25 | Moderate | High |
| Lafuente, 2015 | Antiarrythmics | Use or not | 51 | 9420/13 122 | OR | 0.433(0.374, 0.500) | 0.0000 | No | 63.43% | Yes | No | >25 | Moderate | High |
| Lafuente, 2015 | Class Ia | Class Ia vs. control | 8 | 1214/1716 | OR | 0.507(0.404, 0.637) | 0.0000 | No | 0% | No | No | >25 | Moderate | High |
| Lafuente, 2015 | Class Ib | Class Ib vs. control | 2 | 1092/1321 | OR | 0.845(0.631, 1.132) | 0.259 | NA | 0% | NA | NP | >25 | N/S | High |
| Lafuente, 2015 | Class Ic | Class Ic vs. control | 11 | 1010/1765 | OR | 0.357 (0.290, 0.441) | 0.0000 | No | 0% | No | NP | >25 | Moderate | High |
| Lafuente, 2015 | Class I | Class I vs. control | 21 | 3316/4802 | OR | 0.441(0.362, 0.538) | 0.0000 | No | 40.61% | Yes | Yes | >25 | Moderate | High |
| Lafuente, 2015 | Class III | Class III vs. control | 27 | 5693/8004 | OR | 0.428 (0.428, 0.529) | 0.0000 | Yes | 72.12% | Yes | No | >25 | Moderate | High |
| Lafuente, 2015 | Disopyramide | Disopyramide vs. other Class I antiarrythmics | 2 | 53/113 | OR | 0.755(0.358, 1.590) | 0.459 | NA | 0% | NA | NP | >25 | N/S | High |
| Lafuente, 2015 | Amiodarone | Amiodarone vs. Class I drugs | 5 | 371/643 | OR | 0.356(0.239, 0.532) | 0.0000 | Yes | 31.41% | No | NP | >25 | Moderate | High |
| Lafuente, 2015 | Class III | Class III drugs vs. Class I drugs | 13 | 1772/2875 | OR | 0.811(0.588, 1.119) | 0.201 | Yes | 69.68% | No | NP | >25 | N/S | High |
| Schneider 2010 | RAAS | Use or not | 8 | 990/3044 | RR | 0.53 (0.33, 0.85) | 0.009 | Yes | 0% | No | Yes | N/R | Low | Critically Low |
| Post-ablation | ||||||||||||||
| Chen 2016 | Short-term Antiarrythmics (early recurrence of AF) | Use or not | 6 | 1129/2667 | RR | 0.679 (0.526, 0.877) | 0.003 | Yes | 58.38% | Yes | Yes | >25 | Moderate | High |
| Chen 2016 | Short-term Antiarrythmics (late recurrence of AF) | Use or not | 6 | 849/ 2655 |
RR | 0.917 (0.917, 1.023) | 0.120 | Yes | 0% | No | NP | >25 | N/S | High |
CE, class of evidence; CI, confidence interval; ES, effect size; ESB, excess significance bias; GLE, GRADE level of evidence; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; I2, heterogeneity; K, number of studies for each factor; LS, largest study with significant effect; n, number of cases; N, total number of cohort per factor; NA, not assessable; NP, not pertinent because the number of observed studies is less than the expected; NR, not reported; OR, odds ratio; PI, prediction interval; RoB, risk of bias; RR, risk ratio; SSE, small study effects.